Skip to main content
Clinical Trials/EUCTR2009-017416-33-DE
EUCTR2009-017416-33-DE
Active, not recruiting
Not Applicable

Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol.

Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University0 sitesDecember 21, 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Male and female patients with Parkinson´s disease meeting UKPDS criteria
Sponsor
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
Status
Active, not recruiting
Last Updated
12 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 21, 2009
End Date
TBD
Last Updated
12 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University

Eligibility Criteria

Inclusion Criteria

  • signed informed consent according to GCP\-V and local law;
  • male or female patients with Parkinson´s disease with at least 3 of the following symptoms: Resting tremor, Bradykinesia, Rigor and Asymmetria;
  • Age between 30 and 75 years;
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range
  • signed informed consent according to GCP\-V and local law;

Exclusion Criteria

  • Allergic reaction to Entacapon or Tolcapon or their ingredients in the medical history;
  • Atypic parkinson Syndromes (drug induced, metabolic or by inflammation);
  • clinically significant changes in routine lab testing and/or other internal or psychiatric diseases not according to parkinson´s disease;
  • clinically signifikant changes in the general examination not according to parkinson´s disease;
  • Diseases with changes in absorption, distribution or metabolism;
  • deep brain stimulation in the medical history;
  • pregnancy, planned pregnancy or nursing period, unwillingness to perform adequate contraception.
  • Allergic reaction to Entacapon or Tolcapon or their ingredients in the medical history;
  • Atypic parkinson Syndromes (drug induced, metabolic or by inflammation);
  • clinically significant changes in routine lab testing and/or other internal or psychiatric diseases not according to parkinson´s disease;

Outcomes

Primary Outcomes

Not specified

Similar Trials